Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Oxybutinyn Vaginal Ring · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Oxybutinyn Vaginal Ring 4mg | EXPERIMENTAL | inserted daily and replaced every 4 weeks |
| Oxybutinyn Vaginal Ring 6mg | EXPERIMENTAL | inserted daily and replaced every 4 weeks |
| Name | Type | Description |
|---|---|---|
| Oxybutinyn Vaginal Ring 4mg | DRUG | - |
| Oxybutinyn Vaginal Ring 6mg | DRUG | - |
Inclusion Criteria: * Completed the 12 weeks of treatment in the DR-OXY-301 study * Willing to limit medications for overactive bladder to investigational product only * Able to understand and complete all study procedures including the required diary
Oxybutynin Vaginal Ring is an investigational small molecule being developed for the treatment of overactive bladder. It is designed for use in female patients aged 18 years and older. The drug is currently in Phase 3 clinical development and has not been approved by regulatory authorities.
Oxybutynin Vaginal Ring is being developed by Teva Pharmaceutical Industries Limited, a company traded on the stock exchange under the ticker symbol TEVA. The drug is currently in Phase 3 clinical trials for the treatment of overactive bladder.
Oxybutynin Vaginal Ring is in Phase 3 clinical development. It is an investigational drug for overactive bladder and has not yet received regulatory approval. One Phase 3 clinical trial has been completed, involving 240 female participants.
Oxybutynin Vaginal Ring has one completed Phase 3 clinical trial registered as NCT00782769, titled 'A Safety Extension Study of DR-OXY-301'. This randomized, double-blind, controlled study enrolled 240 female patients with overactive bladder in the United States.
Oxybutynin Vaginal Ring is also known as DR-OXY-301, as indicated by the clinical trial title 'A Safety Extension Study of DR-OXY-301'. This alternative name is used in the context of the Phase 3 clinical trial for overactive bladder.